Profile of immunoglobulins, clinical and bacteriological cure after different treatment routes of clinical bovine mastitis

ABSTRACT The present study aimed to evaluate the profile of immunoglobins profile, clinical and bacteriological cure after different treatment routes of clinical bovine mastitis. Here, 30 Holstein cows with clinical mastitis in one quarter were uniformly divided into: 10 dairy cows that received 8.5mg of cefquinome sulphate administrated intramammarily during three consecutive milkings and 2.5mg/kg of enrofloxacin administrated parenterally during three consecutive days (Group 1); 10 dairy cows that received 8.5mg of cefquinome sulphate administrated intramammarily during three consecutive milkings (Group 2); and 10 dairy cows that received 2.5mg/kg of enrofloxacin administrated parenterally during three consecutive days (Group 3). Milk samples for somatic cell count, California Mastitis Test (CMT), bacteriological culture and quantification of IgG1, IgG2, IgM and IgA were collected before antimicrobial treatment, and after two, five and 12 days after the antimicrobial treatment. The combined treatment was more effective in the clinical cure rate, reduction of somatic cell count and CMT scores. Furthermore, the results demonstrated that milk concentration of different Igs classes were not related to prognosis of bovine clinical mastitis, and then cannot be considered as robust markers associated with clinical and bacteriological cures.摘要：本研究旨在评估临床型牛乳腺炎经不同给药途径治疗后的免疫球蛋白谱、临床转归与细菌学治愈效果。本研究将30头单乳区患临床型乳腺炎的荷斯坦奶牛（Holstein cows）均分为三组：第1组为连续3次挤奶时经乳房内注射8.5mg硫酸头孢喹肟（cefquinome sulphate），同时连续3天给予2.5mg/kg恩诺沙星（enrofloxacin）胃肠外给药的10头泌乳奶牛；第2组为仅连续3次挤奶时经乳房内注射8.5mg硫酸头孢喹肟的10头泌乳奶牛；第3组为仅连续3天给予2.5mg/kg恩诺沙星胃肠外给药的10头泌乳奶牛。于抗菌治疗前，以及抗菌治疗后第2、5、12天采集奶样，用于体细胞计数、加州乳腺炎试验（California Mastitis Test, CMT）、细菌培养以及IgG1、IgG2、IgM、IgA的定量检测。结果显示，联合给药方案在临床治愈率、体细胞计数降低及CMT评分改善方面效果更优。此外，研究结果表明，奶样中不同免疫球蛋白（Immunoglobins, Igs）类别的浓度与牛临床乳腺炎的预后无显著关联，因此无法作为与临床及细菌学治愈相关的可靠标志物。